AbSci is a global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry. The company\'s SoluPro™ expression platform achieves revolutionary yields of soluble and active protein product across a diverse range of targets. AbSci\'s unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/25/16 | $5,100,000 | Series A |
Phoenix Venture Partners | undisclosed |
| 05/30/18 | $12,000,000 | Series C |
Asahi Glass Columbia Ventures Greenbridge Investment Partners Oregon Venture Fund Phoenix Venture Partners Souther Co. WRF Capital | undisclosed |
| 02/22/21 | undisclosed | Strategic |
Merck Global Health Innovation Fund | undisclosed |
